NO20083243L - Pyrazoler for behandling av GERD og IBS - Google Patents

Pyrazoler for behandling av GERD og IBS

Info

Publication number
NO20083243L
NO20083243L NO20083243A NO20083243A NO20083243L NO 20083243 L NO20083243 L NO 20083243L NO 20083243 A NO20083243 A NO 20083243A NO 20083243 A NO20083243 A NO 20083243A NO 20083243 L NO20083243 L NO 20083243L
Authority
NO
Norway
Prior art keywords
treatment
ibs
alkyl
hydrogen
compounds
Prior art date
Application number
NO20083243A
Other languages
English (en)
Inventor
Udo Bauer
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20083243L publication Critical patent/NO20083243L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår nye pyrazolderivater som har en positiv allosterisk GABAB reseptor (GBR) modulerende effekt, fremgangsmåter for fremstilling av nevnte forbindelser og deres anvendelse, eventuelt i kombinasjon med en GABAB agonist, for inhibering av forbigående lavere spiserørlukkemuskelrelaksasjoner, for behandling av gastrospiserørreflukssykdom, så vel som for behandling av funksjonelle gastrointestinale forstyrrelser og irritabelt tarmsyndrom (IBS). Forbindelsene er representert ved den generelle formelen (I), hvori R1, R2, R3 og Y er som definert i beskrivelsen. For eksempel kan R1 være hydrogen eller alkyl, R2 kan være hydrogen eller alkyl, R3 kan være alkoksy, og Y kan være en karbonylaminobundet substituent som inneholder en arylgruppe.
NO20083243A 2005-12-23 2008-07-22 Pyrazoler for behandling av GERD og IBS NO20083243L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0502908 2005-12-23
PCT/SE2006/001461 WO2007073297A1 (en) 2005-12-23 2006-12-21 Pyrazoles for the treatment of gerd and ibs

Publications (1)

Publication Number Publication Date
NO20083243L true NO20083243L (no) 2008-07-23

Family

ID=38188928

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083243A NO20083243L (no) 2005-12-23 2008-07-22 Pyrazoler for behandling av GERD og IBS

Country Status (12)

Country Link
US (1) US20090062365A1 (no)
EP (1) EP1966150A4 (no)
JP (1) JP2009521427A (no)
KR (1) KR20080090449A (no)
CN (1) CN101341128A (no)
AU (1) AU2006327314A1 (no)
BR (1) BRPI0620415A2 (no)
CA (1) CA2632011A1 (no)
IL (1) IL191765A0 (no)
NO (1) NO20083243L (no)
WO (1) WO2007073297A1 (no)
ZA (1) ZA200805240B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2007073300A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
EP1968946A4 (en) * 2005-12-23 2010-05-05 Astrazeneca Ab IMIDAZOLE AS MODULATORS OF THE GABA B RECEPTOR
US7745474B2 (en) * 2005-12-23 2010-06-29 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
US20080312291A1 (en) * 2005-12-23 2008-12-18 Udo Bauer Heterocyclic Gaba-b Modulators
CA2886895C (en) 2012-10-02 2021-10-19 Bayer Cropscience Ag Heterocyclic compounds as pesticides
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3876655A (en) * 1971-08-18 1975-04-08 Beecham Group Ltd Anti-inflammatory acyl imidazoles
US3833582A (en) * 1972-08-21 1974-09-03 Pfizer Herbicidal 1h-pyrazolo(3,4-d)pyrimidin-4-ones
US3910907A (en) * 1973-07-09 1975-10-07 Icn Pharmaceuticals Pyrazolo(1,5-a)-1,3,5-triazines
FR2264015A1 (en) * 1974-03-13 1975-10-10 Pfizer Pyrazolo(3,4-d)pyrimidin-4-ones - pre-and post-emergence herbicides
JPS5758670A (en) * 1980-09-25 1982-04-08 Otsuka Chem Co Ltd 1-methyl-3-(n-substituted-n-chloroacetylamino)pyrazole-4-carboxylic acid ester derivative
US4659720A (en) * 1982-12-20 1987-04-21 Merck & Co., Inc. 5-amino or substituted amino imidazoles useful to treat coccidiosis
DD240013A1 (de) * 1985-04-01 1986-10-15 Univ Halle Wittenberg Verfahren zur herstellung von n-(1h-pyrazol-3-yl)-oxamaten
US5214063A (en) * 1990-06-27 1993-05-25 Adir Et Compagnie 4-aminobutyric acid compounds, compositions and methods of use for treating disorders related to a dysfunction of GABAB receptors
FR2663934B1 (fr) * 1990-06-27 1994-06-03 Adir Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
US5201938A (en) * 1991-07-19 1993-04-13 Dowelanco N-pyrazolyl-1,2,4-triazolo[1,5-c]pyrimidine-2-sulfonamide herbicides
DE4213750A1 (de) * 1992-04-25 1993-10-28 Basf Ag Verfahren zur Herstellung von 3-(Hydroxyphenyl)-propionaldehyden und gegebenenfalls der Herstellung von 3-(hydroxyphenyl)-propanolen
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
EP0983260A2 (en) * 1997-05-22 2000-03-08 G.D. Searle & Co. 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
AU7726898A (en) * 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6409988B1 (en) * 1999-07-01 2002-06-25 3-Dimensional Pharmaceuticals, Inc. Radiolabeled 1-aryl pyrazoles, the synthesis thereof and the use thereof as pest GABA receptor ligands
WO2001007413A1 (en) * 1999-07-22 2001-02-01 3-Dimensional Pharmaceuticals, Inc. 1-aryl-3-thioalkyl pyrazoles, the synthesis thereof and the use thereof as insecticides
GB0024807D0 (en) * 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
JP2002114765A (ja) * 2000-10-11 2002-04-16 Fuji Photo Film Co Ltd ３−アミノ−４−カルボニルピラゾール化合物の製造方法
US20040259883A1 (en) * 2001-09-14 2004-12-23 Hiroshi Sakashita Thiazolidine derivative and medicinal use thereof
WO2003035621A1 (en) * 2001-10-22 2003-05-01 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
JP2003201271A (ja) * 2001-10-25 2003-07-18 Sankyo Co Ltd 脂質モジュレーター
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7589116B2 (en) * 2003-04-03 2009-09-15 Merck & Co. Inc. Biaryl substituted pyrazoles as sodium channel blockers
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
DE102005042583A1 (de) * 2005-09-08 2007-03-15 Bayer Healthcare Ag Iminooxazolidin-Derivate und ihre Verwendung
US7745474B2 (en) * 2005-12-23 2010-06-29 Astrazeneca Ab Imidazole derivatives for the treatment of gastrointestinal disorders
WO2007073300A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Gaba-b receptor modulators
EP1968946A4 (en) * 2005-12-23 2010-05-05 Astrazeneca Ab IMIDAZOLE AS MODULATORS OF THE GABA B RECEPTOR
US20080312291A1 (en) * 2005-12-23 2008-12-18 Udo Bauer Heterocyclic Gaba-b Modulators
US20080262064A1 (en) * 2007-04-18 2008-10-23 Astrazeneca Ab Novel Compounds For The Treatment Of GI Disorders 682
BRPI0810019A2 (pt) * 2007-04-18 2014-10-14 Astrazeneca Ab Composto, composição farmacêutica, e, uso de um composto

Also Published As

Publication number Publication date
WO2007073297A1 (en) 2007-06-28
US20090062365A1 (en) 2009-03-05
BRPI0620415A2 (pt) 2011-11-08
IL191765A0 (en) 2008-12-29
JP2009521427A (ja) 2009-06-04
ZA200805240B (en) 2009-04-29
KR20080090449A (ko) 2008-10-08
CN101341128A (zh) 2009-01-07
CA2632011A1 (en) 2007-06-28
EP1966150A1 (en) 2008-09-10
EP1966150A4 (en) 2011-07-20
AU2006327314A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
NO20083248L (no) Imidazoler som GABA-B reseptormodulatorer
NO20083247L (no) GABA-B reseptormodulatorer
NO20083243L (no) Pyrazoler for behandling av GERD og IBS
NO20083244L (no) Heterosykliske GABA-B modulatorer
NO20083249L (no) Imidazolderivater for behandling av gastrointestinale forstyrrelser
NO20085140L (no) Nye indazolderivater som har spiro ringstruktur i sidekjede
NO20082243L (no) Fremgangsmater og forbindelser for fremstiliing av CC-1065 analoger
UA95454C2 (uk) Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
NO20073114L (no) Amidforbindelse
NO20085385L (no) Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav
SMT201300085B (it) Composti di pirrolo
EA201170096A1 (ru) Замещенные производные пиримидона
PE20130774A1 (es) Compuestos heterociclicos activadores de ampk y metodos para emplearlos
MX2009008465A (es) Nuevas 2-aminooxazolinas como ligandos de taar1.
NO20084262L (no) Nye 1,2,3,4-tetrahydrokinoksalinderivater som har glukokortikoidreseptorbindende aktivitet
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
PE20091425A1 (es) Derivados de aminotiazol
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
WO2010015355A3 (en) Acylaminobenzamide derivatives
EA200971044A1 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
MX2009011922A (es) Tetrahidrobenzazepinas ariloxi- y heteroariloxi-sustituidas y uso de las mismas para bloquear reabsorcion de norepinefrina, dopamina y serotonina.
DK2197860T3 (da) Nye forbindelser som adenosin-A1-receptorantagonister
WO2010003084A3 (en) Phosphodiesterase 4 inhibitors
MX2010009092A (es) Nuevos derivados de 3-aminoalquil-1,3-dihidro-2h-indol-2-ona, su preparacion y su aplicacion en terapeutica.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application